Key Takeaways
- FAA controller shortages have led to significant flight disruptions, including a 90-minute average delay at Washington National Airport (DCA) and 161-minute delays at Orlando International Airport (MCO), exacerbated by a month-long government shutdown.
- Novo Nordisk (NVO) has launched a $9 billion unsolicited bid for obesity biotech Metsera (MTSR), challenging Pfizer's (PFE) existing $7.3 billion agreement and igniting a fierce bidding war in the rapidly growing obesity drug market.
- Nissan (NSANY) projects a substantial $1.82 billion (275 billion yen) operating loss for fiscal year 2025, primarily due to the impact of U.S. tariffs and intense market competition, despite a narrowed first-half loss.
Air Travel Disrupted by FAA Staffing Crisis Amid Government Shutdown
U.S. air travel faced significant disruptions on Thursday as the Federal Aviation Administration (FAA) grappled with severe air traffic controller staffing shortages, a problem intensified by the ongoing government shutdown. Washington National Airport (DCA) experienced a ground stop and subsequent ground delays averaging 90 minutes, while Orlando International Airport (MCO) saw departing flights held back with average delays of 161 minutes, or over two and a half hours. The FAA warned that Orlando Airport would have no certified controllers later in the day, effectively halting landings.
The month-long federal government shutdown is a critical factor, forcing approximately 13,000 air traffic controllers and 50,000 Transportation Security Administration (TSA) officers to work without pay. This financial strain has led to an increase in sick calls, putting immense pressure on an already understaffed system. Transportation Secretary Sean Duffy noted that the FAA was already short by about 3,500 air traffic controllers before the shutdown, with many working mandatory overtime and six-day weeks. Such delays, while frustrating for travelers, are implemented by the FAA as a safety measure when controller staffing levels are insufficient.
Metsera at Center of $9 Billion Obesity Biotech Bidding War Between Novo Nordisk and Pfizer
The burgeoning obesity drug market, projected to reach $100 billion to $150 billion by 2030, has ignited a fierce bidding war over U.S. biotech firm Metsera (MTSR). Novo Nordisk (NVO), the Danish pharmaceutical giant known for Wegovy and Ozempic, submitted an unsolicited proposal to acquire Metsera for up to $9 billion. This offer includes $6.5 billion in upfront cash ($56.50 per share) and an additional $2.5 billion in contingent value rights (CVRs) tied to specific development and regulatory milestones.
Novo Nordisk's bid directly challenges an existing agreement between Metsera and Pfizer (PFE), which valued the acquisition at up to $7.3 billion, comprising $4.9 billion upfront ($47.50 per share) and up to $2.4 billion in milestones. Metsera's board has deemed Novo Nordisk's proposal "superior," triggering a four-business-day window for Pfizer to present a counter-offer. Pfizer, in response, has vehemently criticized Novo Nordisk's bid as "reckless" and an "attempt by a company with a dominant market position to suppress competition," vowing to explore all legal avenues to enforce its original agreement. Metsera's pipeline, including a once-monthly GLP-1 injectable (MET-097i) in Phase 2b and an oral prospect in Phase 1, makes it a highly attractive target for companies vying for a stronger position in the lucrative weight-loss therapeutics space. Metsera's shares surged 24.4% on the news.
Nissan Forecasts $1.8 Billion Operating Loss for Fiscal 2025 Amid Tariff Headwinds
Japanese automaker Nissan Motor Co. (NSANY) announced a projected operating loss of 275 billion yen (approximately $1.82 billion) for the current fiscal year, which ends in March 2026. This significant forecast is primarily attributed to the persistent impact of U.S. tariffs and intense competition in the global automotive market. The company also highlighted anticipated challenges in the second half of the fiscal year, including ongoing supply chain risks, foreign exchange volatility, and other external factors.
Despite the grim full-year outlook, Nissan reported a narrowed operating loss of 30 billion yen for the first half (April-September 2025), a substantial improvement from its earlier forecast of a 180 billion yen loss. This better-than-expected first-half performance was driven by one-time benefits, such as lower costs related to emissions regulations and the deferral of some project expenses to the latter half of the year. The company's full-year net income outlook remains undetermined, and its consolidated sales forecast for fiscal 2025 has been revised down from 12.5 trillion yen to 11.7 trillion yen. Nissan previously reported a net loss of 671 billion yen for fiscal year 2024 and has been undergoing a restructuring plan that includes 20,000 job cuts and plant closures.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.